Literature DB >> 6284656

A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.

M Nuti, Y A Teramoto, R Mariani-Costantini, P H Hand, D Colcher, J Schlom.   

Abstract

We report here both the range and patterns of reactivity of an IgG1 monoclonal antibody, B72.3, prepared against human, metastatic mammary carcinoma cells. When the avidin-biotin complex (ABC) immunoperoxidase technique was used on tissue sections, monoclonal B72.3 reacted with 19 of 41 (46%) primary mammary carcinomas and 13 of 21 (62%) metastatic lesions, either in axillary lymph nodes or at distal sites. Variable concentrations of antigen, recognized by B72.3, were observed among mammary tumors, as well as among different cell populations of a given tumor mass. Several patterns of antigen distribution were observed: membrane, diffuse cytoplasmic, focal and marginal. No reactivity was observed to normal mammary epithelium, stroma, or lymphocytes of the breast, nor to any cell types in a variety of other normal human tissues, melanomas, and sarcomas. Reactivity with all of four colon carcinomas was also observed. Assay of serial sections of mammary carcinomas with B72.3 and a monoclonal antibody directed against carcinoembryonic antigen demonstrated that these antigens were both distinct and non-coordinately expressed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284656     DOI: 10.1002/ijc.2910290509

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  52 in total

Review 1.  Functional aspects of glycoprotein N-linked oligosaccharide processing by human tumours.

Authors:  C S Foster
Journal:  Br J Cancer Suppl       Date:  1990-07

2.  Evaluation of impact of immunocytochemical techniques in cytological diagnosis of neoplastic effusions.

Authors:  A Linari; G Bussolati
Journal:  J Clin Pathol       Date:  1989-11       Impact factor: 3.411

Review 3.  Simple sugars to complex disease--mucin-type O-glycans in cancer.

Authors:  Matthew R Kudelka; Tongzhong Ju; Jamie Heimburg-Molinaro; Richard D Cummings
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

4.  Genetic engineering of high affinity anti-human colorectal tumour mouse/human chimeric antibody.

Authors:  J Xiang; Z Chen
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

5.  Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.

Authors:  M A Reddish; L Jackson; R R Koganty; D Qiu; W Hong; B M Longenecker
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

Review 6.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

7.  A 3-dimensional tumor growth inhibition assay for testing monoclonal antibody cytotoxicity.

Authors:  W Z Wei; R J Massey; G H Heppner
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.

Authors:  P H Hand; A Thor; D Wunderlich; R Muraro; A Caruso; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

9.  Immunohistochemical reactivity of a monoclonal antibody prepared against human breast carcinoma.

Authors:  R Mariani-Costantini; M I Colnaghi; F Leoni; S Mènard; S Cerasoli; F Rilke
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

10.  Production of a bifunctional hybrid molecule B72.3/metallothionein-1 by protein engineering.

Authors:  J Xiang; J Koropatnick; Y Qi; X Luo; T Moyana; K Li; Y Chen
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.